Skip to main content
. Author manuscript; available in PMC: 2024 Nov 19.
Published in final edited form as: Trends Cancer. 2024 Apr 5;10(5):383–385. doi: 10.1016/j.trecan.2024.03.009

Figure 1. Phase 1 clinical trial of the MYC-targeted protein therapeutic, OMO-103.

Figure 1.

Treatment of patients with advanced solid tumors with OMO-103 shows preliminary clinical benefit with minimal toxicity. Future studies will be necessary to further elucidate these results. Figure created with BioRender. Abbreviation: ctDNA, circulating tumor DNA.